Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors
Kohli, J.D.; Weder, A.B.; Goldberg, L.I.; Ginos, J.Z.
Journal of Pharmacology and Experimental Therapeutics 213(2): 370-374
1980
ISSN/ISBN: 0022-3565 PMID: 7365696 Document Number: 163852
Document emailed within 1 workday
Related Documents
Tadori, Y.; Kobayashi, H. 2014: The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors Nihon Shinkei Seishin Yakurigaku Zasshi 34(5-6): 127-132Hoffmann, I.S.; Talmaciu, R.K.; Cubeddu, L.X. 1986: Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release Journal of Pharmacology and Experimental Therapeutics 238(2): 437-446
Kurihara, T.; Yamada, T.; Yamamoto, A.; Kawase, M.; Motohashi, N.; Sakagami, H.; Molnár, J. 2004: Relationship between electronic structure and cytotoxic activity of dopamine and 3-benzazepine derivatives In Vivo 18(4): 443-447
Krause, M.; Rouleau, A.; Stark, H.; Garbarg, M.; Schwartz, J.C.; Schunack, W. 1996: Structure-activity relationships of novel azomethine prodrugs of the histamine H3-receptor agonist (R)-alpha-methylhistamine: from alkylaryl to substituted diaryl derivatives Die Pharmazie 51(10): 720-726
Girbes, A.R.; van Veldhuisen, D.J.; Smit, A.J. 1991: Dopamine agonists, a new perspective in cardiovascular therapy? Netherlands Journal of Medicine 39(1-2): 65-71
Breese, G.R.; Baumeister, A.A.; McCown, T.J.; Emerick, S.G.; Frye, G.D.; Crotty, K.; Mueller, R.A. 1984: Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine Journal of Pharmacology and Experimental Therapeutics 231(2): 343-354
McClelland, D.L.; Nakamoto, B.K.; Rosenkranz, R.P. 1987: Cardiovascular effects of centrally administered dopamine agonists and clonidine in the rat Proceedings of the Western Pharmacology Society 30: 243-247
Dwoskin, L.P.; Zahniser, N.R. 1986: Robust modulation of [3H]dopamine release from rat striatal slices by D-2 dopamine receptors Journal of Pharmacology and Experimental Therapeutics 239(2): 442-453
Katzman, R.; Makman, M.H.; Ahn, H.S.; Mishra, R.K.; Gardner, E. 1977: Effects of drugs and lesions on dopamine-stimulated adenylate cyclase: evidence for different classes of dopamine receptors Transactions of the American Neurological Association 102: 76-79
Camerman, N.; Chan, L.Y.; Camerman, A. 1979: Stereochemical characteristics of dopamine agonists: molecular structure of bromocriptine and structural comparisons with apomorphine Molecular Pharmacology 16(3): 729-736
Amenta, F.; Ricci, A. 1991: Dopamine receptors in the cardiovascular system Functional Neurology 6(3): 219-222
Pavoni, V.; Verri, M.; Ferraro, L.; Volta, C.A.; Paparella, L.; Capuzzo, M.; Pavanelli, L.; Buccoliero, C.; Beani, L.; Alvisi, R.; Gritti, G. 1998: Plasma dopamine concentration and effects of low dopamine doses on urinary output after major vascular surgery Kidney International. Suppl 66: S75-S80
Domino, E.F.; Sheng, J. 1993: Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys Journal of Pharmacology and Experimental Therapeutics 265(3): 1387-1391
Kohli, J.D.; Goldberg, L.I.; Volkman, P.H.; Cannon, J.G. 1978: N,N-Di-n-propyl dopamine: a qualitatively different dopamine vascular agonist Journal of Pharmacology and Experimental Therapeutics 207(1): 16-22
Krivonos, O.V.; Fedorova, N.V.; Chigir', I.P. 2004: A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(1): 24-30
Neve, K.A.; Henningsen, R.A.; Kinzie, J.M.; De Paulis, T.; Schmidt, D.E.; Kessler, R.M.; Janowsky, A. 1990: Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand Journal of Pharmacology and Experimental Therapeutics 252(3): 1108-1116
Allen, E.; Pettigrew, A.; Frank, D.; Thompson, S.; Myers, C.; Yamashita, T.; Blumer, J.L. 1997: Alterations in dopamine clearance and catechol-O-methyltransferase activity by dopamine infusions in children Critical Care Medicine 25(1): 181-189
Li, R.L.; Zhang, W.S.; Wang, J.C.; Poe, M. 1987: Structure-activity relationships of the inhibition of Escherichia coli dihydrofolate reductase (MB1428) by 5-(substituted phenyl) thio and 5-(substituted phenyl) seleno-2,4-diaminopyrimidines Yao Xue Xue Bao 22(3): 233-237
Ebert, B.; Madsen, U.; Johansen, T.N.; Krogsgaard-Larsen, P. 1991: NMDA receptor agonists: relationships between structure and biological activity Advances in Experimental Medicine and Biology 287: 483-487
Verimer, T.; Long, J.P.; Bhatnagar, R.K.; Koble, D.L.; Cannon, J.G.; Flynn, J.R.; Goodale, D.B.; Arnerić, S.P. 1981: Dopamine receptor stimulating activity of 5-hydroxy-6-methyl-2-aminotetralin derivatives Archives Internationales de Pharmacodynamie et de Therapie 250(2): 221-241